Alpha Cognition Inc. reported strong early commercial momentum for ZUNVEYL in the second quarter of 2025, with the product ordered in over 300 long-term care (LTC) facilities across priority regions. Notably, 65% of these facilities placed repeat orders, indicating strong clinical confidence in the therapy.
The company's sales team engaged more than 3,700 healthcare professionals during the quarter, successfully generating both new and repeat prescriptions for ZUNVEYL. Clinician feedback consistently highlighted ZUNVEYL's cognitive and behavioral benefits, alongside its favorable tolerability profile.
Alpha Cognition also secured its first national Medicare Part D contract, which includes no prior authorization requirements. This achievement enhances patient access to ZUNVEYL ahead of schedule, a crucial factor for market penetration in the long-term care segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.